According to a new report published by Introspective Market Research, titled, Pharmaceutical Analytical Testing Market by Service Type, End-User, and Region, The Global Pharmaceutical Analytical Testing Market Size Was Valued at USD 8.40 Billion in 2023 and is Projected to Reach USD 17.84 Billion by 2032, Growing at a CAGR of 8.73%.The Pharmaceutical Analytical Testing Market is a critical component of the drug development and manufacturing process, encompassing a wide range of services that ensure the quality, safety, efficacy, and regulatory compliance of pharmaceutical products. These services include stability testing, bioanalytical testing, method development and validation, and raw material testing, among others. The market has gained significant momentum in recent years due to the rising complexity of pharmaceutical formulations and the increasing demand for outsourcing analytical capabilities to specialized service providers.
With the global expansion of the pharmaceutical and biopharmaceutical sectors, regulatory bodies have intensified quality standards, further elevating the need for precise and reliable analytical testing. Moreover, the shift toward biologics, biosimilars, and personalized medicine has accelerated the adoption of advanced analytical platforms. Companies are also increasingly outsourcing testing services to reduce operational costs, improve time-to-market, and gain access to specialized expertise. As innovation in therapeutics continues to grow, the demand for analytical testing is poised for consistent expansion.
The Pharmaceutical Analytical Testing Market is segmented into Service Type, End-User, and Region. By Service Type, the market is categorized into (Bioanalytical Testing, Method Development & Validation, Stability Testing, Raw Material Testing, Others). By End-User, the market is categorized into (Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, Others). By Region, the market is categorized into (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa).
A primary growth driver for the Pharmaceutical Analytical Testing Market is the increasing trend of outsourcing analytical services by pharmaceutical and biopharmaceutical companies. Outsourcing allows organizations to leverage specialized testing capabilities, reduce capital expenditure, and accelerate product development timelines. Moreover, outsourcing ensures compliance with international regulatory standards, which is crucial for product approvals. As the complexity of drug molecules increases—particularly in biologics and biosimilars—external analytical expertise becomes critical for comprehensive characterization, stability analysis, and quality assurance, thereby driving market demand.
One of the significant opportunities in the Pharmaceutical Analytical Testing Market lies in the growing demand for biosimilars and biopharmaceuticals. As patent expirations of blockbuster biologics continue, biosimilars are rapidly gaining market traction, particularly in emerging economies. Analytical testing plays a pivotal role in demonstrating biosimilarity in terms of efficacy, safety, and structure. This expanding pipeline offers vast opportunities for analytical service providers to support development, validation, and regulatory submission processes. Additionally, advancements in analytical technologies such as mass spectrometry and high-throughput screening offer avenues for innovation and enhanced service offerings.
Pharmaceutical Analytical Testing Market, Segmentation
The Pharmaceutical Analytical Testing Market is segmented on the basis of Service Type, End-User, and Region.
Segment A
The Service Type segment is further classified into Bioanalytical Testing, Method Development & Validation, Stability Testing, Raw Material Testing, and Others. Among these, the Bioanalytical Testing sub-segment accounted for the highest market share in 2023. This dominance is attributed to the increasing development of biologics and biosimilars, which require comprehensive bioanalytical assessments to meet regulatory standards. These services support pharmacokinetic (PK), pharmacodynamic (PD), bioequivalence, and immunogenicity studies, essential for drug approval and commercialization. The segment also benefits from growing investments in clinical trials, especially in the oncology and rare disease areas.
Segment B
The End-User segment is further classified into Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations, and Others. Among these, the Pharmaceutical Companies sub-segment accounted for the highest market share in 2023. This segment leads due to the growing need for quality assurance, regulatory compliance, and risk mitigation throughout the drug development lifecycle. Pharmaceutical companies are increasingly partnering with third-party testing providers to manage the volume and complexity of analytical procedures, particularly in large-scale drug manufacturing and global supply chains. This trend is expected to continue as regulatory scrutiny intensifies globally.
Some of The Leading/Active Market Players Are–
- Eurofins Scientific (Luxembourg)
- SGS SA (Switzerland)
- Charles River Laboratories (USA)
- WuXi AppTec (China)
- Intertek Group plc (UK)
- Thermo Fisher Scientific Inc. (USA)
- PPD Inc. (USA)
- Pace Analytical Services (USA)
- Boston Analytical (USA)
- Envigo (USA)
- Almac Group (UK)
- Catalent, Inc. (USA)
- Exova Group (UK)
- Laboratory Corporation of America Holdings (USA)
- Medpace Holdings, Inc. (USA)
- … and other active players.
Key Industry Developments
In June 2024, Eurofins Scientific expanded its bioanalytical testing capabilities by opening a new state-of-the-art laboratory in Switzerland.
The facility is equipped with advanced LC-MS/MS and ELISA technologies, aimed at supporting biologics and biosimilar development. This move enhances Eurofins’ global footprint and strengthens its position in offering end-to-end services for bioanalytical research.
In December 2023, Charles River Laboratories collaborated with Valence Discovery to integrate AI-based drug discovery solutions into their analytical workflow.
The partnership focuses on improving speed and accuracy in lead optimization and analytical validation. By combining AI with laboratory services, Charles River aims to accelerate time-to-market for new therapeutics while ensuring stringent analytical standards.
Key Findings of the Study
- Bioanalytical Testing led the service type segment in 2023 due to biologics growth.
- Pharmaceutical Companies are the largest end-users, driving market demand.
- North America dominates the market owing to advanced R&D infrastructure.
- Outsourcing trends and biologic drug development are major growth drivers.
- AI and high-throughput platforms are reshaping analytical testing landscapes.
